Modality
Vaccine
MOA
Anti-Tau
Target
PI3Kα
Pathway
Autophagy
Prostate CaALL
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Aug 2028
Phase 1Current
NCT08714659
249 pts·ALL
2023-01→2027-11·Completed
NCT07970999
2,800 pts·ALL
2018-02→2028-08·Not yet recruiting
3,049 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-11-071.6y awayPh2 Data· ALL
2028-08-122.4y awayPh2 Data· ALL
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Not yet…
P1/2
Complet…
Catalysts
Ph2 Data
2027-11-07 · 1.6y away
ALL
Ph2 Data
2028-08-12 · 2.4y away
ALL
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08714659 | Phase 1/2 | ALL | Completed | 249 | DOR |
| NCT07970999 | Phase 1/2 | ALL | Not yet recr... | 2800 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 |